当前位置:首页 - 行情中心 - 海辰药业(300584) - 财务分析 - 利润表

海辰药业

(300584)

  

流通市值:28.33亿  总市值:41.40亿
流通股本:8210.99万   总股本:1.20亿

利润表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、营业总收入160,335,652.32671,048,953.77471,526,892.93308,572,571.42
  营业收入160,335,652.32671,048,953.77471,526,892.93308,572,571.42
二、营业总成本142,276,527.05589,280,857.55424,895,894.17268,183,609.26
  营业成本34,560,181.92117,354,830.3478,373,687.3843,561,139.37
  税金及附加3,596,382.6415,442,631.5910,224,134.896,608,200.11
  销售费用48,077,744237,191,494.07195,516,916.62128,610,941.18
  管理费用50,082,140.95172,213,376.93104,692,101.8569,016,888.31
  研发费用4,505,218.3740,458,484.1131,204,448.1816,902,144.44
  财务费用1,454,859.176,620,040.514,884,605.253,484,295.85
  其中:利息费用1,445,754.946,658,907.724,924,553.613,525,526.13
  其中:利息收入10,287.1359,119.8249,557.9537,528.3
三、其他经营收益
  加:公允价值变动收益--22,693,335.71--
  加:投资收益-1,469,012.98-3,592,696.24-2,763,924.66-1,225,456.46
  资产处置收益-1,067.99482,279.37482,279.37482,279.37
  资产减值损失(新)-2,035,581.32-10,545,747.51-14,640,368.67-9,351,690.62
  信用减值损失(新)478,544.7-375,516.891,442,428.33716,669.92
  其他收益173,906.281,345,356.28723,521.08664,082.56
四、营业利润15,205,913.9646,388,435.5231,874,934.2131,674,846.93
  加:营业外收入97,676.273,793,395.613,578,515.8631,311.29
  减:营业外支出319,131.072,881,755.94603,476.23375,787.15
五、利润总额14,984,459.1647,300,075.1934,849,973.8431,330,371.07
  减:所得税费用-1,349,662.686,568,034.672,655,340.72,451,894.32
六、净利润16,334,121.8440,732,040.5232,194,633.1428,878,476.75
(一)按经营持续性分类
  持续经营净利润16,334,121.8440,732,040.5232,194,633.1428,878,476.75
(二)按所有权归属分类
  归属于母公司股东的净利润17,362,971.742,058,385.1132,678,503.3229,157,742.41
  少数股东损益-1,028,849.86-1,326,344.59-483,870.18-279,265.66
  扣除非经常损益后的净利润17,515,079.3260,276,671.3529,543,089.628,851,005.73
七、每股收益
  (一)基本每股收益0.140.350.270.24
  (二)稀释每股收益0.140.350.270.24
九、综合收益总额16,334,121.8440,732,040.5232,194,633.1428,878,476.75
  归属于母公司股东的综合收益总额17,362,971.742,058,385.1132,678,503.3229,157,742.41
  归属于少数股东的综合收益总额-1,028,849.86-1,326,344.59-483,870.18-279,265.66
公告日期2026-04-252026-04-252025-10-232025-08-23
审计意见(境内)标准无保留意见
TOP↑